TABLE 4.

Risk of mortality according to cumulative use of Huaier in unmatched and matched cohorts.

Strata	Total	Death	Crude HR (95%CI)	Adjusted HR (95%CI)
Unmatched cohort
Non-Huaier users	652	465	1 (References)	1 (References)
Huaier users	174	63	0.32 (0.24–0.42) p < 0.001	0.41 (0.31–0.54) p < 0.001
3–12 months	101	45	0.42 (0.31–0.57) p < 0.001	0.50 (0.36–0.69) p < 0.001
12–24 months	52	16	0.25 (0.15–0.41) p < 0.001	0.31 (0.18–0.52) p < 0.001
>24 months	21	2	0.07 (0.02–0.29) p < 0.001	0.09 (0.01–0.67) p = 0.019
Matched cohort
Non-Huaier users	340	196	1 (References)	1 (References)
Huaier users	170	63	0.49 (0.36–0.65) p < 0.001	0.36 (0.26–0.49) p < 0.001
3–12 months	98	45	0.66 (0.48–0.92) p = 0.014	0.48 (0.34–0.67) p < 0.001
12–24 months	51	16	0.37 (0.23–0.63) p < 0.001	0.23 (0.14–0.40) p < 0.001
>24 months	21	2	0.11 (0.03–0.43) p = 0.002	0.16 (0.04–0.64) p = 0.010

Adjusted for age, sex, ALB, γ-GGT, platelets, AFP, MELD, score; BCLC, stage, tumor multiplicity, tumor size, and type of treatment. Abbreviations: ALB, albumin; γ-GGT, γ-glutamyl transferase; AFP, alpha-fetoprotein; MELD, Model for End-Stage Liver Disease; BCLC, barcelona clinic liver cancer; HR, hazard ratio; CI, confidence interval. Bold values: p < 0.05.